4.5  mg/m 
 L (0.45%) solution for injection, this medicinal product contains 0.18  g sodium per 180  m 
 L at the maximal dose, equivalent to 9.0% of the WHO recommended maximum daily intake of 2  g sodium for an adult.  
 Traceability  
 In or der to improve traceability of biological medicinal products, the name an d the batch number of the administered product should be clearly recorded.  
 
4.5 Interaction  with  other  medicinal  products  and other  forms  of interaction   
 No interaction studies have been performed. Based on the potential inhibitory effect of eculizumab on  complement -dependent cytotoxicity of rituximab, eculizumab may reduce the expected pharmacodynamic  effects  of rituximab.  
 
 Concomitant use of eculizumab  with intravenous immunoglobulin (IVIg ) may reduce effectiveness of eculizumab . Closely monitor for reduced effectiveness of eculizumab . 
 Concomitant use of eculizumab  with neonatal Fc receptor (Fc 
 Rn) blockers may lower systemic exposures and reduce effectiveness of eculizumab . Closely monitor for reduced effectiveness of eculizumab . 
 
